References
- Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, et al. Clinician’s Guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10): 2359-81.
- Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21(2):115-37.
- World Helth Organization. Prevention and management of osteoporosis: report of a WHO scientific group. 2003;7-31.
- Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23-57.
- Crockford D, Addington D. Canadian Schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders. Can J Psychiatry. 2017;62(9):624-34.
- National Institute for Health and Clinical Excellence (NICE). Psychosis and Schizophrenia in Adults. Treatment and Management. NICE Clinical Guideline No.178. National Collaborating Centre for Mental Health (UK). London: National Institute for Health and Clinical Excellence; 2014.
- Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163–91.
- Dar HY, Azam Z, Anupam R, Mondal RK, Srivastava RK. Osteoimmunology: The Nexus between bone and immune system. Front Biosci, Landmark. 2018;23(3):464-92.
- Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol. 2007;143(1):31-48.
- Reul, JM. Making memories of stressful events: a journey along epigenetic, gene transcription, and signaling pathways. Front Psychiatry. 2014;5,5.
- Gilad VH, Rabey JM, Eliyayev Y, Gilad GM. Different effects of acute neonatal stressors and long-term postnatal handling on stress-induced changes in behavior and in ornithine decarboxylase activity of adult rats. Brain Res Dev Brain Res. 2000;120(2):255-9.
- Ray A, Gulati K, Rai N. Stress, anxiety, and immunomodulation: a pharmacological analysis. Vitam Horm. 2017;103:1-25.
- Balõtšev R, Haring L, Koido K, Leping V, Kriisa K, Zilmer M, et al. Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study. Early Interv Psychiatry. 2019; 13(1):101-9.
- Vancampfort D, Wampers M, Mitchell AJ, Correll CU, De Herdt A, et al. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013;12(3):240-50.
- Hussain T, Margoob MA, Shoib S, Shafat M, Chandel RK. Prevalence of Metabolic Syndrome among Psychiatric Inpatients: A Hospital Based Study from Kashmir. J Clin Diagn Res. 2017;11(6):VC05-VC08.
- Sjo CP, Stenstrøm AD, Bojesen AB, Frølich JS, Bilenberg N. Development of metabolic syndrome in drug-naive adolescents after 12 months of second-generation antipsychotic treatment. J Child Adolesc Psychopharmacol. 2017;27(10):884-91.
- Popović I, Ravanić D, Janković S, Milovanović D, Folić M, Stanojević A, et al. Long-term treatment with olanzapine in hospital conditions: prevalence and predictors of the metabolic syndrome. Srp Arh Celok Lek. 2015;143(11-12):712-8.
- Gomez L, Stubbs B, Shirazi A, Vancampfort D, Gaughran F, Lally J. Lower bone mineral density at the hip and lumbar spine in people with psychosis versus controls: a comprehensive review and skeletal site-specific meta-analysis. Curr Osteoporos Rep. 2016;14(6):249-59.
- Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79-104.
- Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409.
- Chen CY, Lane HY, Lin CH. Effects of antipsychotics on bone mineral density in patients with schizophrenia: gender differences. Clin Psychopharmacol Neurosci. 2016;14(3):238-49.
- Haddad PM, Wieck A. antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-314.
- Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008;18(2):S108-S114.
- Bulut SD, Bulut S, Tüzer V, Mehmet AK, Emine AK, Cebrail KISA, et al. The effects of prolactin-raising and prolactin-sparing antipsychotics on prolactin levels and bone mineral density in schizophrenic patients. Noro Psikiyatr Ars. 2014;51(3):205-10.
- Kane JM, Correll CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci. 2010;12(3):345–57.
- Scigliano G, Ronchetti G. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis. CNS Drugs. 2013;27(4):249-57.
- Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231-41.
- Vieweg V, Hasnain M. Schizophrenia, antipsychotic drugs, and drug induced weight gain and obesity. Expert Rev Neurother. 2012;26(1):19-22.
- Kishimoto T, Watanabe K, Shimada N, Makita K, Yagi G, Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69(3):385-91.
- Golob AL, Laya MB. Osteoporosis: screening, prevention, and management. Med Clin North Am. 2015;99(3):587-606.
- Cilotti A, Falchetti A. Male osteoporosis and androgenic therapy: from testosterone to SARMs. Clin Cases Miner Bone Metab. 2009;6(3):229–33.
- Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab. 2012;23(11):576-81.
- Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C. Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance. L'encephale. 2014;40(1):86-94.
- Milano W, D’Acunto CW, De Rosa M, Festa M, Milano L, et al. A. Recent clinical aspects of hyperprolactinemia induced by antipsychotics. Rev Recent Clin Trials. 2011;6(1):52-63.
- Wang M, Hou R, Jian J, Mi G, Qiu H, et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Hum Psychopharmacol. 2014;29(2):183-9.
- Okita K, Kanahara N, Nishimura M, Yoshida T, Yasui-Furukori N, Niitsu T, et al. Second-generation antipsychotics and bone turnover in shizophrenia. Schizophr Res. 2014;157(1-3):137-41.
- Lodhi RJ, Masand S, Malik A, Shivakumar K, McAllister VD, O’Keane V, et al. Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study. Schizophr Res. 2016;170(2-3):245-51.
- De Hert M, Detraux J, Stubbs B. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review. Expert Opin Drug Saf. 2016;15(6):809-23.
- Wu H, Deng L, Zhao L, Zhao J, Li L, Chen J. Osteoporosis associated with antipsychotic treatment in schizophrenia. Int J Endocrinol. 2013;1-7.
- Tseng PT, Chen YW, Yeh PY, Tu KY, Cheng YS, Wu CK. Bone mineral density in schizophrenia: An up-date of current meta-analysis and literature review under guideline of PRISMA. Medicine. 2015;94(47):e1967.
- González-Blanco L, Greenhalgh AMD, Garcia-Rizo C, Fernandez-Egea E, Miller BJ, Kirkpatrick B. Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: a meta-analysis. Schizophr Res. 2016;174(1-3):156-60.
- Gomez L, Stubbs B, Shirazi A, Vancampfort D, Gaughran F, Lally J. Lower bone mineral density at the hip and lumbar spine in people with psychosis versus controls: a comprehensive review and seletal site-specific meta-analysis. Curr Osteoporos Rep. 2016;14(6):249-259.
- Zhang B, Deng L, Wu H, Lu X, Peng L, Wu R, et al. Relationship between long-term use of a typical antipsychotic medication by Chinese schizophrenia patients and the bone turnover markers serum osteocalcin and β-CrossLaps. Schizophr Res. 2016;176(2-3):259-63.
- Bozec A, Zaiss MM. T regulatory cells in bone remodelling. Curr Osteoporos Rep. 2017;15(3):121-5.
- Liu H, Luo T, Tan J, Li M, Guo J. Osteoimmunology’ Offers New Perspectives for the Treatment of Pathological Bone Loss. Curr Pharm Des. 2017;23(41):6272-8.
- Azizieh F, Raghupathy R, Shehab D, Al-Jarallah K, Gupta R. Cytokine profiles in osteoporosis suggest a proresorptive bias. Menopause. 2017;24(9):1057-64.
- De Pablo P, Cooper MS, Buckley CD. Association between bone mineral density and C-reactive protein in a large population-based sample. Arthritis Rheum. 2012;64(8):2624-31.
- Borovcanin MM, Jovanovic I, Radosavljevic G, Pantic J, Minic Janicijevic S, Arsenijevic N, Lukic ML. Interleukin-6 in Schizophrenia-Is there a therapeutic relevance? Front Psychiatry. 2017;8:221.
- Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, et al. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev Bras de Psiquiatr. 2011;33(3):268-74.
- Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Stefanovic V, et al. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. Schizophr Res. 2013;147(1):103-9.
- Cui J, Liu H, Shao J, Xu DM, Wang Y, Fei Z, et al. Prevalence, risk factors and clinical characteristics of osteoporosis in Chinese inpatients with schizophrenia. Schizophr Res. 2018;195:488-94.
- Vancampfort D, Knapen J, Probst M, Scheewe T, Remans S, De Hert M. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand. 2012;125(5):352-62.
- Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231–41.
- Freyberg Z, Aslanoglou D, Shah R, Ballon JS. Intrinsic and antipsychotic drug-induced metabolic dysfunction in schizophrenia. Front Neurosci. 2017;11:432.
- Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010;10(3):209-16.
- Curcic D, Stojmenovic T, Djukic-Dejanovic S, Dikic N, Vesic-Vukasinovic M, Radivojevic N, et al. Positive impact of prescribed physical activity on symptoms of schizophrenia: randomized clinical trial. Psychiatr Danub. 2017;29(4):459-65.
- Stubbs B, Gaughran F, Mitchell AJ, De Hert M, Farmer R, Soundy A, et al. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry. 2015;37(2):126-33.
- Pillinger T, D’Ambrosio E, McCutcheon R, D Howes O. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Mol Psychiatry. 2019;24(6):776-94.
- Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385-403.
- Ballon JS, Pajvani U, Freyberg Z, Leibel RL, Lieberman JA. Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends Endocrinol Metab. 2014;25(11):593-600.